SB 203105

Drug Profile

SB 203105

Latest Information Update: 15 Jul 2011

Price : $50

At a glance

  • Originator Pfizer
  • Class Antiparasitics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Trichostrongylosis

Most Recent Events

  • 15 Jul 2011 Discontinued - Preclinical for Trichostrongylosis in United Kingdom (unspecified route)
  • 27 Jul 2000 Profile reviewed but no significant changes made
  • 23 Jun 2000 Pfizer has merged with Warner-Lambert
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top